Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 12/20 | 0.81 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
| ▸ | SRC | P12931 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2570944 | 0.90 | FGFR1 (1.00) | FGFR1KDRSRCRAB9ANPC1 | |
| SCHEMBL5942362 | 0.86 | FGFR1 (0.79) | FGFR1KDRSRCRAB9ANPC1 | |
| SCHEMBL7975748 | 0.82 | FGFR1 (0.81) | FGFR1SRCRAB9AHPGDMAPT | |
| SCHEMBL1812955 | 0.82 | FGFR1 (1.00) | FGFR1SRCRAB9AMAPT | |
| SCHEMBL12135624 | 0.81 | KDR (0.76) | FGFR1KDRSRC | |
| Hydrochloric Acid SCHEMBL7986510 | 0.81 | FGFR1 (0.79) | FGFR1SRCRAB9AHPGDMAPT | |
| SCHEMBL7683792 | 0.81 | KDR (1.00) | FGFR1KDRSRCLMNASMN1; SMN2 | |
| SCHEMBL18584752 | 0.79 | DYRK1A (0.65) | FGFR1SRC | |
| SCHEMBL4502855 | 0.79 | FGFR1 (0.79) | FGFR1RAB9AHPGDMAPT | |
| SCHEMBL23675157 | 0.78 | FGFR1 (0.77) | FGFR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135553-A1 | Imidazole derivatives | PHENOMIX CORPORATION | 2006-06-22 | — | — | US | disclosed |
| WO-2006050162-A2 | IMIDAZOLE DERIVATIVES | PHENOMIX CORPORATION (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135553-A1 | Imidazole derivatives | FLT4, NOS2, FLT1 | FGFR1 140/4885KDR 5/4885SRC 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.